Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism

References

• Grazzini E, Guillon G, Mouillac B, Zingg HH. Inhibition of oxytocin receptor function by direct binding of progesterone. Nature. 1998;392(6675):509–12.
   PubMed Web of Science ®Google Scholar
• Astle S, Slater DM, Thornton S. The involvement of progesterone in the onset of human labour. Eur. J. Obstet., Gynecol., Reproductive Biol. 2003;108(2):177–81.
   PubMed Web of Science ®Google Scholar
• Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am. J. Obstet. Gynecol. 2012;206(2):124 e1–19.
   Web of Science ®Google Scholar
• Astle S, Khan RN, Thornton S. The effects of a progesterone metabolite, 5 beta-dihydroprogesterone, on oxytocin receptor binding in human myometrial membranes. BJOG: an Int. J. Obstet. Gynaecol. 2003;110(6):589–92.
   PubMed Web of Science ®Google Scholar
• Condon JC, Jeyasuria P, Faust JM, Wilson JW, Mendelson CR. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proc. Natl Acad. Sci. United States Am. 2003;100(16):9518–23.
   PubMed Web of Science ®Google Scholar
• Lofgren M, Holst J, Backstrom T. Effects in vitro of progesterone and two 5 alpha-reduced progestins, 5 alpha-pregnane-3,20-dione and 5 alpha-pregnane-3 alpha-ol-20-one, on contracting human myometrium at term. Acta Obstet. Gynecol. Scand. 1992;71(1):28–33.
   PubMed Web of Science ®Google Scholar
• Lofgren M, Backstrom T. Continuous progesterone exposure associated with high contraction frequency in human term myometrial strips. Acta Obstet. Gynecol. Scand. 1994;73(3):186–91.
   PubMed Web of Science ®Google Scholar
• Thornton S, Terzidou V, Clark A, Blanks A. Progesterone metabolite and spontaneous myometrial contractions in vitro. Lancet. 1999;353(9161):1327–9.
   PubMed Web of Science ®Google Scholar
• Perusquia M, Jasso-Kamel J. Influence of 5alpha- and 5beta-reduced progestins on the contractility of isolated human myometrium at term. Life Sci. 2001;68(26):2933–44.
   PubMed Web of Science ®Google Scholar
• Patil AS, Swamy GK, Murtha AP, Heine RP, Zheng X, Grotegut CA. Progesterone metabolites produced by cytochrome P450 3A modulate uterine contractility in a murine model. Reprod Sci. 2015;22(12):1577–86.
   PubMed Web of Science ®Google Scholar
• Swart P, Swart AC, Waterman MR, Estabrook RW, Mason JI. Progesterone 16 alpha-hydroxylase activity is catalyzed by human cytochrome P450 17 alpha-hydroxylase. The J. Clin. Endocrinol. Metab. 1993;77(1):98–102.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch. Biochem. Biophys. 1997;346(1):161–9.
   PubMed Web of Science ®Google Scholar
• Niwa T, Yabusaki Y, Honma K, Matsuo N, Tatsuta K, Ishibashi F, et al. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica; the Fate of Foreign Compounds Biol. Syst. 1998;28(6):539–47.
   Google Scholar
• Schwarz D, Kisselev P, Schunck WH, Chernogolov A, Boidol W, Cascorbi I et al. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000;10(6):519–30.
   PubMedGoogle Scholar
• Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenetics Genomics. 2005;15(9):625–31.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Del. Rev. 2002;54(10):1271–94.
   PubMed Web of Science ®Google Scholar
• Hakkola J, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Cresteil T et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol. 1996;52(2):379–83.
   PubMed Web of Science ®Google Scholar
• Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. 1996;51(4):403–11.
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Kauma S, Guzelian PS. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J. Clin. Invest. 1993;92(2):1018–24.
   PubMed Web of Science ®Google Scholar
• Maezawa K, Matsunaga T, Takezawa T, Kanai M, Ohira S, Ohmori S. Cytochrome P450 3As gene expression and testosterone 6 beta-hydroxylase activity in human fetal membranes and placenta at full term. Biol. Pharm. Bull. 2010;33(2):249–54.
   PubMed Web of Science ®Google Scholar
• Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP et al. Variability of CYP3A7 expression in human fetal liver. J. Pharmacol. Exp. Ther. 2005;314(2):626–35.
   PubMed Web of Science ®Google Scholar
• Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol. Ther. 2014;96(3):340–8.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383–91.
   PubMed Web of Science ®Google Scholar
• Tracy TS, Venkataramanan R, Glover DD, Caritis SN. National Institute for Child H, Human Development Network of Maternal-Fetal-Medicine U. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am. J. Obstet. Gynecol. 2005;192(2):633–9.
   PubMed Web of Science ®Google Scholar
• Hebert MF, Easterling TR, Kirby B, Carr DB, Buchanan ML, Rutherford T et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin. Pharmacol. Ther. 2008;84(2):248–53.
   PubMed Web of Science ®Google Scholar
• Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. A PBPK model to predict disposition of CYP3A-Metabolized drugs in pregnant women: verification and discerning the site of CYP3A induction. CPT: Pharmacomet Syst. Pharmacol. 2012;1:e3.
   PubMedGoogle Scholar
• Quinney SK, Mohamed AN, Hebert MF, Haas DM, Clark S, Umans JG et al. A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: predicting changes in midazolam and nifedipine pharmacokinetics. CPT: Pharmacomet Syst. Pharmacol. 2012;1:e2.
   PubMedGoogle Scholar
• Nanovskaya TN, Deshmukh SV, Nekhayeva IA, Zharikova OL, Hankins GD, Ahmed MS. Methadone metabolism by human placenta. Biochem. Pharmacol. 2004;68(3):583–91.
   PubMed Web of Science ®Google Scholar
• Deshmukh SV, Nanovskaya TN, Ahmed MS. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J. Pharmacol. Exp. Ther. 2003;306(3):1099–105.
   PubMed Web of Science ®Google Scholar
• Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 2010;38(7):1218–29.
   PubMed Web of Science ®Google Scholar
• Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica; the Fate of Foreign Compounds Biol. Syst. 2006;36(6):473–97.
   Google Scholar
• Shuster DL, Risler LJ, Prasad B, Calamia JC, Voellinger JL, Kelly EJ et al. Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem. Pharmacol. 2014;92(4):690–700.
   PubMed Web of Science ®Google Scholar
• Vyhlidal CA, Pearce RE, Gaedigk R, Calamia JC, Shuster DL, Thummel KE et al. Variability in expression of CYP3A5 in human fetal liver. Drug Metab. Dispos. 2015;43(8):1286–93.
   PubMedGoogle Scholar
• ICRP. Basic anatomical and physiological data for use in radiological protection reference values. ICRP publication 89. Ann ICRP. 2002;32(3–4).
   Google Scholar
• Pelkonen O. Drug metabolism in the human fetal liver. Relationship to fetal age. Arch. Int. Pharmacodyn Ther. 1973;202(2):281–7.
   PubMedGoogle Scholar
• Martin JA, Osterman MJ. Preterm births - United States, 2006 and 2010. MMWR Surveill Summ. 2013;62(Suppl 3):136–8.
   Google Scholar
• Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. New England J. Med. 2003;348(24):2379–85.
   PubMed Web of Science ®Google Scholar
• Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet. Gynecol.: Official J. Int. Soc. Ultrasound Obstet. Gynecol. 2011;38(1):18–31.
   Google Scholar
• Niwa T, Murayama N, Imagawa Y, Yamazaki H. Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab. Rev. 2015;47(2):89–110.
   PubMed Web of Science ®Google Scholar
• Jeong S, Woo MM, Flockhart DA, Desta Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro. Cancer Chemother. Pharmacol. 2009;64(5):867–75.
   PubMed Web of Science ®Google Scholar
• Swinney DC. Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5 alpha-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat. Drug Metab. Dispos. 1990;18(6):859–65.
   PubMed Web of Science ®Google Scholar
• Storbeck KH, Swart P, Africander D, Conradie R, Louw R, Swart AC. 16alpha-hydroxyprogesterone: origin, biosynthesis and receptor interaction. Mol. Cell. Endocrinol. 2011;336(1–2):92–101.
   PubMed Web of Science ®Google Scholar